NI-2101
/ Light Chain Biosci, Takeda
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 07, 2017
Newly added product
(Novimmune Press Release)
Pipeline update • Hematological Malignancies • Hemophilia • Oncology
February 14, 2020
Light Chain Bioscience successfully completes factor VIII mimetic bispecific antibody discovery for Takeda
(GlobeNewswire)
- "Light Chain Bioscience...announced that it has achieved a milestone and received a payment under its research and collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda). The milestone was achieved upon the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific antibodies as clinical development candidates...The collaboration aims at developing bispecific antibodies with Factor VIII mimetic activity for the treatment of hemophilia A patients."
Preclinical
1 to 2
Of
2
Go to page
1